Global Implantable Defibrillators Market Report to 2030 -
Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator,...
Stay updated with breaking news from Cardiac Resynchronization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator,...
Que Dallara joins as EVP & President, Diabetes Mike Marinaro named President, Surgical Robotics Dr. Kweli Thompson named President, Cardiac Rhythm Management DUBLIN, March 17, 2022 /PRNewswire/... | March 17, 2022
/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units –...
Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Cardiac Resynchronization Therapy Market Size, Share & Trends Analysis Report by Product...
Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario. BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to ...